Hepatitis C Antibody Screening
This 67-year-old woman should receive one-time universal hepatitis C virus (HCV) antibody screening with reflex HCV RNA testing, as she falls within the recommended age range for universal screening and has never been tested for hepatitis C.
Rationale for HCV Screening
The AASLD-IDSA 2020 guidelines recommend universal, one-time, opt-out HCV screening for all adults aged ≥18 years without an upper age limit 1. This recommendation specifically applies to this patient because:
- She is 67 years old and asymptomatic
- She has no documented prior hepatitis testing
- Universal screening bypasses the inherent barriers in ascertaining accurate risk factor assessment
- The guidelines explicitly state no age limit should be applied due to the excellent quality of life of many octogenarians and the association between advanced age and more rapid HCV disease progression 1
The USPSTF 2020 recommendation differs slightly by setting an upper age limit of 79 years, but this patient at age 67 falls well within both guideline recommendations 2.
Recommended Testing Approach
HCV-antibody testing with reflex HCV RNA polymerase chain reaction (PCR) testing is the recommended initial screening method (Class I, Level A evidence) 1. This approach:
- Uses FDA-approved laboratory-based or point-of-care assays
- Automatically triggers confirmatory RNA testing if antibody is positive
- Distinguishes current active infection from past resolved infection
Why Not Other Tests at This Time?
HIV screening: While her last HIV test was over 20 years ago, the question specifically asks about hepatitis testing given her lack of prior hepatitis screening. HIV screening would be reasonable but is not the primary focus given the clinical context.
Hepatitis B screening: Though she has no documented hepatitis B testing, the strongest and most recent guideline evidence emphasizes universal HCV screening as a public health priority. The 2023 CDC hepatitis B guidelines do recommend universal screening at least once for adults ≥18 years 3, but HCV screening takes precedence given the specific clinical scenario presented.
Important Clinical Context
This patient has no traditional high-risk factors (no injection drug use, monogamous relationship for 40 years, no history of STIs). However, this is precisely why universal screening is recommended—it eliminates the need for risk stratification and captures cases that would otherwise be missed through risk-based screening alone 1.
The rising HCV incidence related to the opioid epidemic and the availability of highly effective direct-acting antiviral therapy make case-finding through universal screening a critical public health strategy aligned with WHO goals to eliminate HCV as a public health threat by 2030 1.
Common Pitfall to Avoid
Do not skip HCV screening based on the absence of traditional risk factors. The guidelines explicitly moved away from risk-based screening to universal screening because many infected individuals do not report or recognize risk factors, and clinicians often fail to elicit accurate risk histories 1.